SLAMF7 and Miyoshi myopathy: In particular, the mAbs used in MM, including the anti-SLAMF7 mAb elotuzumab, the anti-CD38 mAbs daratumumab and isatuximab, and the anti-B cell maturation antigen (BCMA) antibody–drug conjugate belantamab mafadotin, all work in part by promoting antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells [10,11,12,13].